Atossa Therapeutics (ATOS) Asset Writedowns and Impairment (2013 - 2024)
Atossa Therapeutics (ATOS) posted quarterly Asset Writedowns and Impairment of $1.7 million for Q3 2024, up 17000.0% quarter-over-quarter from $10000.0 in Q4 2023.
Atossa Therapeutics (ATOS) Asset Writedowns and Impairment (2013 - 2024) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Asset Writedowns and Impairment for 7 consecutive years, with $1.7 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Asset Writedowns and Impairment changed N/A year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $1.7 million (down 0.58% YoY), while the FY2024 annual figure was $1.7 million, down 43.33% from the prior year.
- Asset Writedowns and Impairment advanced to $1.7 million in Q3 2024 per ATOS's latest filing, from $10000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.7 million in Q3 2024 and bottomed at $10000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.71 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Dec 31, 2023 | 10,000.00 |
| Dec 31, 2023 | 10,000.00 |
| Mar 31, 2019 | 1.74 Mn |
| Mar 31, 2019 | 1.74 Mn |
| Dec 31, 2018 | -2.18 Mn |
| Dec 31, 2018 | -2.18 Mn |
| Sep 30, 2018 | 623,496.00 |
| Sep 30, 2018 | 623,496.00 |
| Dec 31, 2015 | -1.19 Mn |
| Dec 31, 2015 | -1.19 Mn |
| Sep 30, 2015 | 625,499.00 |
| Sep 30, 2015 | 625,499.00 |
| Jun 30, 2015 | 344,212.00 |
| Jun 30, 2015 | 344,212.00 |
| Mar 31, 2015 | 218,482.00 |
| Mar 31, 2015 | 218,482.00 |
| Dec 31, 2014 | 2.27 Mn |
| Dec 31, 2014 | 2.27 Mn |